* Gets FDA final approval for Polyethylene Glycol 3350
* Says product comparable to Schering-Plough drug MiraLAX
* Expects to begin shipping immediately
Oct 6 (Reuters) - Generic drug maker Perrigo Co said it received final marketing approval from the U.S. Food and Drug Administration for its new over-the-counter bowel drug.
The company expects to begin immediate shipping of the drug Polyethylene Glycol 3350, powder for solution, which treats occasional constipation.
Perrigo said it would market the product under store brand labels, and is comparable to MiraLAX, a laxative made by Schering-Plough HealthCare Products', a unit of Schering-Plough Corp.
The company said, the estimated brand sales of MiraLAX for the last 12 months ending Aug. 28 were $200 million.
Shares of the company closed at $34.88 on the Nasdaq.
(Reporting by Krishnakali Sengupta in Bangalore; Editing by Ratul Ray Chaudhuri) Keywords: PERRIGOCO/ (krishnakali.sengupta@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800; Reuters Messaging: krishnakali.sengupta.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Says product comparable to Schering-Plough drug MiraLAX
* Expects to begin shipping immediately
Oct 6 (Reuters) - Generic drug maker Perrigo Co said it received final marketing approval from the U.S. Food and Drug Administration for its new over-the-counter bowel drug.
The company expects to begin immediate shipping of the drug Polyethylene Glycol 3350, powder for solution, which treats occasional constipation.
Perrigo said it would market the product under store brand labels, and is comparable to MiraLAX, a laxative made by Schering-Plough HealthCare Products', a unit of Schering-Plough Corp.
The company said, the estimated brand sales of MiraLAX for the last 12 months ending Aug. 28 were $200 million.
Shares of the company closed at $34.88 on the Nasdaq.
(Reporting by Krishnakali Sengupta in Bangalore; Editing by Ratul Ray Chaudhuri) Keywords: PERRIGOCO/ (krishnakali.sengupta@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800; Reuters Messaging: krishnakali.sengupta.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.